An $18 Billion Hedge Fund Just Bought These 3 Stocks

Chris Arnold • 6 minute read
Reviewed by: Chris Arnold
Last updated Nov 19, 2026

Tevarak Phanduang from Achira22's Images via Canva

Key Takeaways

  • Durable Capital Partners is a hedge fund that manages $17.6 billion, and its 13F shows it added to Shopify and Medline and bought Revvity in the quarter ended Sept. 30.
  • Shopify was the biggest of the three, at 4.5% of the fund’s 13F stocks, and analysts’ average target sits 27% above the last close.
  • Revvity and Medline both trade at about 26x forward earnings, and Revvity’s stock and its targets have already climbed sharply over the past year.
  • Shopify is the one the numbers back best, with a forward P/E below its average of the past year.

Most investors have never heard of Henry Ellenbogen’s Durable Capital Partners, a hedge fund that manages $17.6 billion. Its 13F for the quarter ended Sept. 30, filed Nov. 16, shows six positions that were new or bigger by the end of the quarter.

The three biggest were Shopify (SHOP), Revvity (RVTY) and Medline (MDLN). All three trade below their 52-week highs, and Wall Street sees upside in each.

Shopify got the most money

The fund held 2.98 million Shopify shares at Sept. 30, worth $442 million, after adding 27% to its stake over the quarter. That made it the fund’s No. 11 holding, at 4.5% of its 13F stocks.

Shopify’s third quarter disappointed in early November. Revenue grew 32% to $3.74 billion, in line with expectations. But GMV of $119.1 billion and subscription revenue of $836 million both came in under estimates. The stock is down 6% since Sept. 30.

Analysts didn’t flinch. The consensus target is about where it was a year ago, at $177, after a dip to $147 in July:

Line chart from TIKR of Shopify's analysts' consensus (mean) price target, $ per share, last year.
Shopify (SHOP): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

And the business is still taking share. Management says Shopify merchants have captured nearly half of new US e-commerce dollars since early 2025, citing eMarketer, while holding just over 14% of US e-commerce.

TIKR tracks 54 analysts on Shopify. How many say “Buy”?

See the full breakdown of Buy, Hold, and Sell ratings on Shopify, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Shopify’s Analyst Ratings

Revvity is new, and its comeback is mostly priced in

Revvity is the only one of the three that’s new to the fund: 1.32 million shares worth $202 million at Sept. 30, or 2.1% of its 13F stocks. The stock is down 0.3% since then.

Analysts have warmed up to Revvity for a reason. In July it agreed to sell its China immunodiagnostics business for up to $200 million. Leaving that business out, third-quarter revenue rose to $710 million from $660 million a year earlier, and adjusted EPS rose to $1.37 from $1.13. Revvity credits product mix and restructuring savings for a gross margin that climbed to 57.4% from 53.6%.

The consensus target has climbed from about $114 a year ago to $171:

Line chart from TIKR of Revvity's analysts' consensus (mean) price target, $ per share, last year.
Revvity (RVTY): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

The trouble is that the stock climbed with it, from $93 to $152 over the same year. That leaves the target just 12% above the last close, with the stock at about 26x forward earnings.

Medline’s sales are running ahead of its profit

The fund added 80% to its Medline stake, ending the quarter with 4.73 million shares worth $164 million, or 1.7% of its 13F stocks. The stock is up 13% since Sept. 30. That’s only a price change, though: a 13F doesn’t show what the fund paid, or whether it still holds the shares.

Medline jumped 18% on its third quarter on Nov. 4. Net sales rose 10.4% to $7.86 billion. Medline raised its 2026 outlook for organic sales growth to 10.0%-10.5% from 9.0%-10.0%, and its board authorized a $1 billion buyback.

Profit is the weaker half. Adjusted EBITDA rose 11.8% to $960 million, but that included $81 million of tariff refunds, and without them it grew about 2%. GAAP net income slipped 1.2% to $318 million, which Medline put down to inflation in its inventory costs, higher operating expenses and customer mix.

Analysts haven’t chased the stock. The consensus target has drifted down from $49 in January to $46:

Line chart from TIKR of Medline's analysts' consensus (mean) price target, $ per share, since it listed.
Medline (MDLN): analysts’ consensus (mean) price target, $ per share, since it listed (TIKR)

That’s 16% above the last close, with Medline at about 26x forward earnings.

Shopify’s numbers back the bet best

Shopify trades at about 63x forward earnings. That’s a lot to pay. But it’s below the stock’s average of about 74x over the past year on TIKR, and not far above the 60x it hit at the end of June.

Analysts expect normalized EPS to climb from $1.43 in 2025 to $3.32 in 2028. After the third quarter, they nudged their 2027 revenue estimate up to $19.4 billion from $19.2 billion. The stock is 23% below its high, and the average target from the 54 analysts who cover it sits 27% above the last close, the most upside of the three. The risk is slowing growth: analysts see revenue growth easing from 32% in 2026 to about 26% in 2028. The third quarter also ended Shopify’s run of beating the top of its own revenue guidance.

Of the three, Shopify is the one I’d buy. Revvity’s turnaround is already in its price, and Medline still has to show that its profit can keep up with its sales.

The fund’s next 13F is due in mid-February, around when Shopify reports its fourth quarter. Revenue growth in the low thirties, as Shopify guided, with operating expenses at 29%-30% of revenue, would back the bet.

So what is Shopify stock actually worth?

TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Shopify could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.

Value Shopify for free

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required